144 related articles for article (PubMed ID: 26996321)
1. Proximity-enabled bioreactivity to generate covalent peptide inhibitors of p53-Mdm4.
Hoppmann C; Wang L
Chem Commun (Camb); 2016 Apr; 52(29):5140-3. PubMed ID: 26996321
[TBL] [Abstract][Full Text] [Related]
2. Stapled peptides with improved potency and specificity that activate p53.
Brown CJ; Quah ST; Jong J; Goh AM; Chiam PC; Khoo KH; Choong ML; Lee MA; Yurlova L; Zolghadr K; Joseph TL; Verma CS; Lane DP
ACS Chem Biol; 2013 Mar; 8(3):506-12. PubMed ID: 23214419
[TBL] [Abstract][Full Text] [Related]
3. Helical beta-peptide inhibitors of the p53-hDM2 interaction.
Kritzer JA; Lear JD; Hodsdon ME; Schepartz A
J Am Chem Soc; 2004 Aug; 126(31):9468-9. PubMed ID: 15291512
[TBL] [Abstract][Full Text] [Related]
4. Reactivation of p53: from peptides to small molecules.
Brown CJ; Cheok CF; Verma CS; Lane DP
Trends Pharmacol Sci; 2011 Jan; 32(1):53-62. PubMed ID: 21145600
[TBL] [Abstract][Full Text] [Related]
5. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
6. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
7. Small molecule inhibitors of p53/MDM2 interaction.
Fotouhi N; Graves B
Curr Top Med Chem; 2005; 5(2):159-65. PubMed ID: 15853644
[TBL] [Abstract][Full Text] [Related]
8. Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets?
Fischer PM; Lane DP
Trends Pharmacol Sci; 2004 Jul; 25(7):343-6. PubMed ID: 15219971
[No Abstract] [Full Text] [Related]
9. 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR.
Parks DJ; Lafrance LV; Calvo RR; Milkiewicz KL; Gupta V; Lattanze J; Ramachandren K; Carver TE; Petrella EC; Cummings MD; Maguire D; Grasberger BL; Lu T
Bioorg Med Chem Lett; 2005 Feb; 15(3):765-70. PubMed ID: 15664854
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
Chène P
Mol Cancer Res; 2004 Jan; 2(1):20-8. PubMed ID: 14757842
[TBL] [Abstract][Full Text] [Related]
11. Fragment-based library generation for the discovery of a peptidomimetic p53-Mdm4 inhibitor.
Boltjes A; Huang Y; van de Velde R; Rijkee L; Wolf S; Gaugler J; Lesniak K; Guzik K; Holak TA; Dömling A
ACS Comb Sci; 2014 Aug; 16(8):393-6. PubMed ID: 24983416
[TBL] [Abstract][Full Text] [Related]
12. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53.
García-Echeverría C; Chène P; Blommers MJ; Furet P
J Med Chem; 2000 Aug; 43(17):3205-8. PubMed ID: 10966738
[No Abstract] [Full Text] [Related]
13. In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide.
Ji Y; Majumder S; Millard M; Borra R; Bi T; Elnagar AY; Neamati N; Shekhtman A; Camarero JA
J Am Chem Soc; 2013 Aug; 135(31):11623-11633. PubMed ID: 23848581
[TBL] [Abstract][Full Text] [Related]
14. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53.
Li Z; Day CP; Yang JY; Tsai WB; Lozano G; Shih HM; Hung MC
Cancer Res; 2004 Dec; 64(24):9080-5. PubMed ID: 15604276
[TBL] [Abstract][Full Text] [Related]
15. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
16. Knowledge-based virtual screening: application to the MDM4/p53 protein-protein interaction.
Jacoby E; Boettcher A; Mayr LM; Brown N; Jenkins JL; Kallen J; Engeloch C; Schopfer U; Furet P; Masuya K; Lisztwan J
Methods Mol Biol; 2009; 575():173-94. PubMed ID: 19727615
[TBL] [Abstract][Full Text] [Related]
17. Case Study: discovery of inhibitors of the MDM2-p53 protein-protein interaction.
Liu L; Bernard D; Wang S
Methods Mol Biol; 2015; 1278():567-85. PubMed ID: 25859977
[TBL] [Abstract][Full Text] [Related]
18. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
19. Rapid screening of protein-protein interaction inhibitors using the protease exclusion assay.
Nirantar SR; Li X; Siau JW; Ghadessy FJ
Biosens Bioelectron; 2014 Jun; 56():250-7. PubMed ID: 24508816
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous measurement of p53:Mdm2 and p53:Mdm4 protein-protein interactions in whole cells using fluorescence labelled foci.
Frosi Y; Inoue K; Ramlan SR; Lane DP; Watanabe T; Brown CJ
Sci Rep; 2019 Nov; 9(1):17933. PubMed ID: 31784573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
